MET and cancer: The rationale for dual-targeting of both EGFR and c-MET besides heterogeneous expression is that an interplay between EGFR and c-MET expression is seen in cancer cells, where therapeutic targeting of one receptor leads to compensatory mechanisms and upregulation of the other receptor.61